Integra LifeSciences Q2 2026: Net Income Swings to $4.5M, Guidance Reaffirmed, but Cincinnati Flood Adds Uncertainty
IART sits 87% above its 52-week low of $8.7 on elevated volume (2.4× avg).
Summary
Integra LifeSciences swung to a Q2 profit of $4.5M from a year-ago loss, reaffirmed guidance, but disclosed a flood at its Cincinnati plant that could disrupt operations.
Key Events · Earnings and Guidance · IART
-
Q2 Profit Recovery
Net income of $4.5M vs. a $484.1M loss in Q2 2025, driven by absence of goodwill impairment and improved gross margin to 52.5%.
-
Revenue Growth
Total revenue of $418.8M, up 0.8% year-over-year, with Specialty Surgery up 1.7% and Tissue Reconstruction down 1.9%.
-
Full-Year Guidance Reaffirmed
Management reaffirmed its 2026 adjusted EPS outlook of $2.40–$2.50, signaling confidence despite ongoing tariff and operational challenges.
-
Cincinnati Flood Disruption
A July 17 flood damaged the Cincinnati manufacturing facility; financial impact is being assessed, but insurance coverage is expected to mitigate losses.
Analysis · IART · Industrial Applications And Services
A sharp turnaround defined Integra LifeSciences' Q2 2026, as net income reached $4.5 million versus a $484 million loss a year ago, helped by the absence of last year's goodwill impairment and stronger gross margins. Revenue edged up to $418.8 million. Confidence in the recovery path was underscored by the reaffirmed full-year outlook. Yet a new risk surfaced: a July 17 flood at the Cincinnati manufacturing facility disrupted operations, and the financial impact remains under assessment. Although insurance is expected to cover much of the damage, near-term uncertainty has been introduced. The filing also revealed a new CEO employment agreement and a separation for a former executive, reflecting continued leadership stabilization.
At the time of this filing, IART was trading at $16.24 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $8.70 to $20.49. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.